Subtopic Deep Dive

UDP-Glucuronosyltransferase Pharmacogenetics
Research Guide

What is UDP-Glucuronosyltransferase Pharmacogenetics?

UDP-Glucuronosyltransferase pharmacogenetics studies genetic variants in UGT enzymes that alter glucuronidation rates of drugs and endogenous compounds.

UGT1A1*28 variants reduce bilirubin glucuronidation causing Gilbert's syndrome and increase irinotecan toxicity risk (Jančová et al., 2010). UGT2B7 polymorphisms affect opioid glucuronidation impacting analgesia efficacy (Smith, 2009). Over 500 papers explore UGT haplotypes correlating with glucuronide formation rates.

Curated Papers

Key Challenges

Why It Matters

UGT pharmacogenetics guides irinotecan dosing in cancer patients to prevent severe neutropenia from deficient SN-38 glucuronidation (Jančová et al., 2010). UGT2B7 variants influence morphine glucuronidation affecting opioid dosing in pain management (Smith, 2009). Sex differences in UGT expression require genotype-stratified therapies (Waxman and Holloway, 2009). CPIC guidelines adapt codeine dosing based on related Phase II enzyme genetics, extending to UGT poor metabolizers (Crews et al., 2011).

Key Research Challenges

UGT Variant Functional Prediction

Predicting glucuronidation rates from UGT haplotypes remains imprecise due to linkage disequilibrium and epistasis (Jančová et al., 2010). In vitro assays show variable enzyme activity but lack in vivo correlation (Smith, 2009). Over 100 UGT1A1 SNPs complicate clinical genotyping.

Sex-Specific UGT Expression

Hepatic UGT enzymes exhibit sex differences affecting drug clearance rates (Waxman and Holloway, 2009). Females show higher UGT2B7 activity impacting opioid metabolism differently than males (Smith, 2009). Pediatric developmental changes add further variability (van den Anker et al., 2018).

Clinical Translation Barriers

CPIC guidelines exist for CYP2D6 but lag for UGT variants despite irinotecan toxicity risks (Crews et al., 2011). Interethnic UGT1A1*28 allele frequencies vary widely requiring population-specific dosing (Omiecinski et al., 2010). TDM integration with genotyping is inconsistent (Hiemke et al., 2017).

Essential Papers

Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective

Samik Bindu, Somnath Mazumder, Uday Bandyopadhyay · 2020 · Biochemical Pharmacology · 1.7K citations

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

Christoph Hiemke, N. Bergemann, H.‐W. Clement et al. · 2017 · Pharmacopsychiatry · 1.3K citations

Abstract Therapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood to optimize pharmacotherapy. It considers the interindividual variability of phar...

Sex Differences in the Expression of Hepatic Drug Metabolizing Enzymes

David J. Waxman, Minita G. Holloway · 2009 · Molecular Pharmacology · 794 citations

Opioid Metabolism

Howard S. Smith · 2009 · Mayo Clinic Proceedings · 637 citations

PHASE II DRUG METABOLIZING ENZYMES

Petra Jančová, Pavel Anzenbacher, Eva Anzenbacherová · 2010 · Biomedical Papers · 568 citations

Phase II drug metabolizing enzymes play an important role in biotransformation of endogenous compounds and xenobiotics to more easily excretable forms as well as in the metabolic inactivation of ph...

The Central Role of Cytochrome P450 in Xenobiotic Metabolism—A Brief Review on a Fascinating Enzyme Family

Francisco Esteves, José Rueff, Michel Kranendonk · 2021 · Journal of Xenobiotics · 432 citations

Human Cytochrome P450 (CYP) enzymes constitute a superfamily of membrane-bound hemoproteins that are responsible for the metabolism of a wide variety of clinically, physiologically, and toxicologic...

Developmental Changes in Pharmacokinetics and Pharmacodynamics

John van den Anker, Michael D. Reed, Karel Allegaert et al. · 2018 · The Journal of Clinical Pharmacology · 367 citations

Abstract Effective drug therapy to optimally influence disease requires an understanding of a drug's pharmacokinetic, pharmacodynamic, and pharmacogenomic interrelationships. In pediatrics, age is ...

Reading Guide

Foundational Papers

Start with Jančová et al. (2010) for Phase II UGT overview (568 citations); Smith (2009) for opioid glucuronidation (637 citations); Waxman and Holloway (2009) for sex differences (794 citations) establishing genetic-metabolic links.

Recent Advances

Bindu et al. (2020, 1711 citations) on NSAID-UGT organ damage; Hiemke et al. (2017, 1349 citations) TDM guidelines; van den Anker et al. (2018) on developmental UGT changes.

Core Methods

Genotyping (PCR/sequencing), enzyme kinetics (LC-MS glucuronide quantification), pharmacokinetic modeling (non-compartmental analysis), haplotype association studies (Omiecinski et al., 2010).

How PapersFlow Helps You Research UDP-Glucuronosyltransferase Pharmacogenetics

Discover & Search

Research Agent uses searchPapers('UGT1A1*28 irinotecan toxicity') to find 200+ papers, then citationGraph on Jančová et al. (2010) reveals 568 Phase II enzyme citations clustering UGT pharmacogenetics. exaSearch uncovers rare UGT2B7-morphine studies; findSimilarPapers expands from Smith (2009) opioid metabolism.

Analyze & Verify

Analysis Agent runs readPaperContent on Crews et al. (2011) CPIC guidelines, verifying UGT-codeine analogies via verifyResponse (CoVe). runPythonAnalysis extracts genotype-phenotype correlations from Waxman and Holloway (2009) tables using pandas, with GRADE scoring high-confidence sex differences evidence. Statistical verification confirms UGT activity distributions.

Synthesize & Write

Synthesis Agent detects gaps in UGT2B7 pediatric data via gap detection, flagging contradictions between adult opioid studies (Smith, 2009). Writing Agent uses latexEditText for dosing algorithm sections, latexSyncCitations linking 50 UGT papers, and latexCompile for publication-ready review. exportMermaid generates UGT Phase II pathway diagrams.

Use Cases

"Analyze UGT1A1*28 allele frequencies and irinotecan neutropenia risk across populations"

Research Agent → searchPapers → runPythonAnalysis (pandas frequency tables from 20 papers) → GRADE verification → exportCsv of stratified risks.

"Draft LaTeX review on UGT2B7 polymorphisms in opioid glucuronidation"

Synthesis Agent → gap detection → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (Smith 2009 et al.) → latexCompile → PDF output.

"Find GitHub code for UGT enzyme kinetic modeling"

Research Agent → paperExtractUrls (Jančová 2010) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis (test kinetics script) → exportMermaid (model diagram).

Automated Workflows

Deep Research workflow scans 50+ UGT papers via searchPapers → citationGraph → structured report with Phase II enzyme timelines. DeepScan applies 7-step CoVe to verify UGT1A1*28 toxicity claims from Hiemke et al. (2017) TDM data. Theorizer generates hypotheses linking UGT sex differences (Waxman 2009) to NSAID damage (Bindu 2020).

Try Doxa for UDP-Glucuronosyltransferase Pharmacogenetics Research

Frequently Asked Questions

What defines UDP-Glucuronosyltransferase pharmacogenetics?

Study of UGT genetic variants altering drug glucuronidation, like UGT1A1*28 causing Gilbert's and irinotecan issues (Jančová et al., 2010).

What are key methods in UGT pharmacogenetics?

Haplotyping via PCR, in vitro glucuronidation assays, and pharmacokinetic modeling correlate variants to metabolite rates (Smith, 2009; Jančová et al., 2010).

What are seminal papers?

Waxman and Holloway (2009, 794 citations) on sex differences; Smith (2009, 637 citations) on opioid metabolism; Jančová et al. (2010, 568 citations) on Phase II enzymes.

What open problems exist?

Lack of UGT-specific CPIC guidelines beyond CYP2D6 (Crews et al., 2011); predicting polygenic UGT effects; integrating TDM with genotyping (Hiemke et al., 2017).